Shuang Fan

Shuang Fan

Auto-generated profile, based on publicly available information

Shuang Fan

Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany. 1

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Materials Today Energy
Verified
Journal Article
Closed access
MPMei Er Pam
Mei Er Pam
Shaozhuan HuangShaozhuan Huang
Shaozhuan Huang
SFShuang Fan
Shuang Fan
DGDechao Geng
Dechao Geng
DKDezhi Kong
Dezhi Kong
HYHui Ying Yang
Hui Ying Yang

1 August 2024 in Cancer Research Communications
Verified
Journal Article
Open access
MEMarcus Edelmann
Marcus Edelmann
SFShuang Fan
Shuang Fan
TOTiago De Oliveira
Tiago De Oliveira
TGTina Goldhardt
Tina Goldhardt
DSDorothée Sartorius
Dorothée Sartorius
LCLena Conradi
Lena Conradi
Treatment of patients with locally advanced rectal cancer (RC) is based on neoadjuvant chemoradiotherapy followed by surgery. In order to reduce the development of therapy resistance, it is necessary to further improve previous treatment approaches. Recent in vivo experimental studies suggested that the reduction of tumor hypoxia by tumor vessel normalization (TVN), through the inhibition of the glycolytic activator PFKFB3, could significantly improve tumor response to therapy. We have evaluated in vitro and in vivo the effects of the PFKFB3 inhibitor 2E-3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) on cell survival, clonogenicity, migration, invasion, and metabolism using colorectal cancer cells, patient-derived tumor organoid (PDO), and xenograft (PDX). 3PO treatment of colorectal cancer cells increased radiation-induced cell death and reduced cancer cell invasion. Moreover, gene set enrichment analysis shows that 3PO is able to alter the metabolic status of PDOs toward oxidative phosphorylation. Additionally, in vivo neoadjuvant treatment with 3PO induced TVN, alleviated tumor hypoxia, and increased tumor necrosis. Our results support PFKFB3 inhibition as a possible future neoadjuvant addition for patients with RC. Significance: Novel therapies to better treat colorectal cancer are necessary to improve patient outcomes. Therefore, in this study, we evaluated the combination of a metabolic inhibitor (3PO) and standard radiotherapy in different experimental settings. We have observed that the addition of 3PO increased radiation effects, ultimately improving tumor cell response to therapy.

9 August 2024
Verified
Other
Open access
MEMarcus Edelmann
Marcus Edelmann
SFShuang Fan
Shuang Fan
TOTiago De Oliveira
Tiago De Oliveira
TGTina Goldhardt
Tina Goldhardt
DSDorothée Sartorius
Dorothée Sartorius
LCLena Conradi
Lena Conradi
Supplementary Fig. 6 from Tumor Vessel Normalization via PFKFB3 Inhibition Alleviates Hypoxia and Increases Tumor Necrosis in Rectal Cancer upon Radiotherapy

9 August 2024
Verified
Other
Open access
MEMarcus Edelmann
Marcus Edelmann
SFShuang Fan
Shuang Fan
TOTiago De Oliveira
Tiago De Oliveira
TGTina Goldhardt
Tina Goldhardt
DSDorothée Sartorius
Dorothée Sartorius
LCLena Conradi
Lena Conradi
Supplementary Fig. 2 from Tumor Vessel Normalization via PFKFB3 Inhibition Alleviates Hypoxia and Increases Tumor Necrosis in Rectal Cancer upon Radiotherapy

9 August 2024
Verified
Other
Open access
MEMarcus Edelmann
Marcus Edelmann
SFShuang Fan
Shuang Fan
TOTiago De Oliveira
Tiago De Oliveira
TGTina Goldhardt
Tina Goldhardt
DSDorothée Sartorius
Dorothée Sartorius
LCLena Conradi
Lena Conradi
3PO potentializes irradiation effects in colorectal cancer cells. A, Colony formation assay performed with HCT-116, HT-29, SW-1463, and SW-837 cancer cells upon 3PO treatment. Cells treated with DMSO or 2.5 µmol/L 3PO for 4 hours and exposed to indicated doses of RT. Six days (HCT-116), 7 days (HT-29), and 14 days (SW-1463 and SW-837) later, colonies were stained and counted. Data are displayed as means ± SD, n = 3. ∗, P < 0.05; one-way ANOVA. B, Colony formation assays performed with HCT-116, HT-29, SW-1463, and SW-837 cells treated with different concentrations of 3PO for 4 hours, exposed to either RT (6 Gy) or not irradiated and analyzed after 6 days (HCT-116), 7 days (HT-29), 14 days (SW-1463), and 14 days (SW-837) by counting colonies. C, Invasion assay performed with HCT-116, HT-29, SW-1463, and SW-837 cancer cells. Cells were plated in a Boyden multi-well chamber and treated with 10 µmol/L 3PO for 4 hours, subjected to RT (6Gy), and incubated for a period of 96 hours. Data are displayed as means SD, n = 3. ∗∗, P < 0.01; ∗∗∗∗, P < 0.0001; one-way ANOVA. D–F Cell migration assay quantification of HCT-116, HT-29, and SW-837 cancer cells upon combinatory treatment. Cells were treated with 3PO for 4 hours and subjected to RT (6 Gy). Data are displayed as means ± SD, n = 3. ∗, P < 0.05; ∗∗, P < 0.01; ∗∗∗, P < 0.001; ∗∗∗∗, P < 0.0001; one-way ANOVA.